YORK, Pa., Aug. 25, 2015 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS and ASX: UNS), a developer, manufacturer and supplier of injectable drug delivery systems, today announced the appointment of Mr. Harry Hamill to the Board of Directors, the appointment of Ms. Mary Kate Wold as Lead Independent Director, and the retirement of Mr. Jim Bosnjak after 12 years of service.
Mr. Hamill, 61, is a seasoned financial executive in the public company life sciences sector, who prior to his retirement held several senior finance positions at Wyeth. During Mr. Hamill's 18-year career at Wyeth, he held various executive roles, including leading global Mergers and Acquisitions, Vice-President of Finance for Wyeth's global manufacturing and distribution operations, CFO of a global animal health business unit, and Corporate Vice President and Deputy Controller. Prior to his career at Wyeth, Mr. Hamill was a Partner at a large regional public accounting firm. He is a Certified Public Accountant and a graduate of Baruch College.
Mr. Alan Shortall, Chairman and CEO of Unilife said: "It is with great pleasure that I welcome Harry Hamill to our Board of Directors. Harry brings a strong combination of finance, operations and M&A experience in the life sciences industry to Unilife, and I expect he will provide seasoned and wise leadership to the Company."
Appointment of Mary Kate Wold as Lead Independent Director
Ms. Mary Kate Wold, who joined the Unilife Board in 2010 and is Chief Executive Officer of the Church Pension Fund, has been appointed as Vice Chair and Lead Independent Director. She will also continue to serve as Chair of the Strategic Partnerships Committee and as a member of the Audit Committee and Nominating and Governance Committee.
Mr. Shortall said: "Mary Kate Wold has provided Unilife with strong and independent counsel since her appointment to our Board as a Director in 2010. With her appointment as Lead Independent Director, I expect her contributions to Unilife will become even more valuable moving forward."
Retirement of Jim Bosnjak
Mr. Jim Bosnjak, 66, has advised Unilife of his decision to retire from the Board for health reasons. Mr Bosnjak was first appointed to the Unilife Board in 2003 and served as Chairman between 2006 and 2013. Mr. Bosnjak will continue to serve as a strategic advisor to the Board as his health permits.
Mr. Alan Shortall said: "Jim has been a wonderful supporter of Unilife for more than a decade. As a former Chairman and long-term member of our Board, Jim has made significant contributions towards our growth and expansion. On behalf of the Board and management team of Unilife, I thank Jim for his service and wish him a speedy recovery. I also look forward to Jim's continued counsel to me and the Board as his health and time allow."
About Unilife Corporation
Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's portfolio of innovative, differentiated products includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, insulin patch pumps, ocular delivery systems and novel systems. Products within each platform are customizable to address specific customer, drug and patient requirements. Unilife's global headquarters and manufacturing facilities are located in York, PA. For more information, visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.
SOURCE Unilife Corporation